- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02811185
Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose
An Open-label, Non-randomized Study to Monitor for Adverse Drug Reactions Among Patients Administered Fedoruk-manufactured [F-18]-FDG Injection
Study Overview
Status
Intervention / Treatment
Detailed Description
This study will document the use of Fedoruk-manufactured [F-18]-FDG Injection (citrate formulation) in patients referred for [F-18]-FDG PET or PET/CT imaging at Royal University Hospital (RUH) in Saskatoon, SK. This investigational agent is produced using procedures, raw materials, equipment and quality standards that are equivalent to commercially-approved [F-18]-FDG Injection (Glucovision®, manufactured by the CPDC in Hamilton ON).
This is a single-centre, open-label, non-randomized study to monitor for adverse drug reactions among subjects administered Fedoruk-manufactured [F-18]-FDG Injection. Eligible subjects are those who would normally be referred by their physician for [F-18]-FDG PET or PET/CT imaging at RUH in Saskatoon, SK.
The primary goal of this study is to permit immediate access, with appropriate regulatory and REB oversight, to Fedoruk-manufactured [F-18]-FDG Injection pending commercial approval.
Monitoring for adverse drug reactions, during and after subjects are administered Fedoruk-manufactured [F-18]-FDG Injection, will support the primary objective of this study. Based on the well-established safety profile of [F-18]-FDG and the comparability of Fedoruk-manufactured [F-18]-FDG Injection to commercially-approved [F-18]-FDG Injection (Glucovision®), it is not expected that any ADRs will be observed.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Referred by treating physician to receive [F-18]-FDG and PET or PET/CT imaging;
- Meets all current local clinical criteria for receiving [F-18]-FDG and PET or PET/CT imaging;
- Ability to understand and the willingness to sign, or (in the case of paediatric patients) a parent/guardian who understands and is willing to sign, a written informed consent document;
Exclusion Criteria:
- Pregnant women; all women of child-bearing potential will have a confirmed negative urine pregnancy test prior to administration of [F-18]-FDG Injection;
- Subjects unwilling or unable to stop breast feeding for 24 hours;
- Subjects who are medically unstable, based on the Principal Investigator's assessment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: PET/CT Scan
Subjects will receive a single dose of [F-18]-FDG Injection at Visit 1, followed by PET/CT scanning according to departmental practice.
|
Radiopharmaceutical imaging agent
Other Names:
|
Other: PET Scan
Subjects will receive a single dose of [F-18]-FDG Injection at Visit 1, followed by PET scanning according to departmental practice.
|
Radiopharmaceutical imaging agent
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Document any adverse drug reactions, following administration of [F-18]-FDG Injection.
Time Frame: 1 day
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rajan Rakheja, MD, Saskatoon Health Region
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FED001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Positron-Emission Tomography and Cone-Beam Computed Tomography
-
Cairo UniversityUnknownCone Beam Computed TomographyEgypt
-
Cairo UniversityUnknownCone-Beam Computed TomographyEgypt
-
Abramson Cancer Center at Penn MedicineVarian Medical SystemsRecruiting
-
Cairo UniversityRecruiting
-
Maastricht University Medical CenterAdvanced BionicsUnknownCochlear Implantation | Cone-Beam Computed TomographyNetherlands
-
Fayoum UniversityCompletedCone Beam Computed Tomography | Mental ForamenEgypt
-
Recep Tayyip Erdogan University Training and Research...UnknownCone-Beam Computed TomographyTurkey
-
Universidad Científica del SurNYU Langone HealthCompletedDental Implants | Bone Regeneration | Cone-beam Computed Tomography | Bone Substitutes | Bone TransplantationPeru
-
Cairo UniversityNot yet recruitingMaxillary Sinus | Cone-beam Computed Tomography | Midface | Volumetric Analysis
-
Ankara UniversityCompletedDental Implants | Cone-beam Computed Tomography | Submandibular Fossa Depth | Gonial Angle | Panoramic RadiographyTurkey
Clinical Trials on [F-18]-Fludeoxyglucose
-
Abramson Cancer Center of the University of PennsylvaniaNational Cancer Institute (NCI)TerminatedCervical CancerUnited States
-
University of UtahTerminatedMalignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma... and other conditionsUnited States
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI)TerminatedLung CancerUnited States
-
Chang Gung Memorial HospitalCompleted
-
University of WashingtonNational Cancer Institute (NCI)TerminatedRecurrent Breast Carcinoma | Estrogen Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7United States
-
University Hospital, BrestCompletedUnspecified Adult Solid Tumor, Protocol Specific | ThromboembolismFrance
-
Children's Hospital of PhiladelphiaTerminatedNeurofibromatosis Type 1 | Precancerous ConditionUnited States
-
Chang Gung Memorial HospitalCompletedFrontotemporal Dementia | Progressive Supranuclear Palsy | Alzheimer's Disease | Vascular Cognitive Impairment | Cortical Basal SyndromeTaiwan
-
Siemens Molecular ImagingFudan UniversityCompletedHead and Neck Cancer | Lung Cancer | Liver CancerChina